Cytokine Levels in Conversion Disorder

This study has been completed.

Sponsor:

Information provided by:

Trakya University

ClinicalTrials.gov Identifier:

NCT00971360

First received: September 2, 2009

Last updated: October 19, 2010

Last verified: September 2009

History of Changes

Tracking Information
First Received Date ^ICMJE	September 2, 2009
Last Updated Date	October 19, 2010
Start Date ^ICMJE	September 2009
Primary Completion Date	September 2010 (final data collection date for primary outcome measure)
Current Primary Outcome Measures ^ICMJE	Not Provided
Original Primary Outcome Measures ^ICMJE	Not Provided
Change History	Complete list of historical versions of study NCT00971360 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures ^ICMJE	Not Provided
Original Secondary Outcome Measures ^ICMJE	Not Provided
Current Other Outcome Measures ^ICMJE	Not Provided
Original Other Outcome Measures ^ICMJE	Not Provided

Descriptive Information
Brief Title ^ICMJE	Cytokine Levels in Conversion Disorder
Official Title ^ICMJE	Proinflammatory Cytokine Levels in Patients With Conversion Disorder
Brief Summary	The aim of this study is whether the proinflammatory cytokine levels in patients with conversion disorder is increased or not changed in the acute phase and subacute - chronic periode, compared with controls.
Detailed Description	Not Provided
Study Type ^ICMJE	Observational
Study Design ^ICMJE	Observational Model: Cohort Time Perspective: Prospective
Target Follow-Up Duration	Not Provided
Biospecimen	Not Provided
Sampling Method	Non-Probability Sample
Study Population	primary care clinic
Condition ^ICMJE	Conversion Disorder
Intervention ^ICMJE	Other: conversion disorder Proinflammatory cytokine levels in conversion disorder
Study Group/Cohort (s)	Conversion disorder Intervention: Other: conversion disorder Healthy control Intervention: Other: conversion disorder
Publications *	Rief W, Pilger F, Ihle D, Bosmans E, Egyed B, Maes M. Immunological differences between patients with major depression and somatization syndrome. Psychiatry Res. 2001 Dec 31;105(3):165-74. Ziemssen T, Kern S. Psychoneuroimmunology--cross-talk between the immune and nervous systems. J Neurol. 2007 May;254 Suppl 2:II8-11. Review. Erratum in: J Neurol. 2008 Feb;255(2):309-10. Dantzer R. Somatization: a psychoneuroimmune perspective. Psychoneuroendocrinology. 2005 Nov;30(10):947-52. Review.
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.

Recruitment Information
Recruitment Status ^ICMJE	Completed
Estimated Enrollment ^ICMJE	30
Completion Date	September 2010
Primary Completion Date	September 2010 (final data collection date for primary outcome measure)
Eligibility Criteria ^ICMJE	Inclusion Criteria: Clinical diagnosis of Alzheimer's Disease Exclusion Criteria: Autoimmune disease Neurological disease Any organic disorder that could possibly affect proinflammatory cytokines Pregnancy Any drug usage within 2 weeks Any active or passive immunization within 6 months Any other DSM-IV axis I psychiatric disorder Mental retardation Developmental disorder of childhood
Gender	Both
Ages	18 Years to 65 Years
Accepts Healthy Volunteers	No
Contacts ^ICMJE	Contact information is only displayed when the study is recruiting subjects
Location Countries ^ICMJE	Turkey

Administrative Information
NCT Number ^ICMJE	NCT00971360
Other Study ID Numbers ^ICMJE	TUTFEK 2009/173
Has Data Monitoring Committee	No
Responsible Party	Trakya University Scientific Research Unit (TUBAB)
Study Sponsor ^ICMJE	Trakya University
Collaborators ^ICMJE	Not Provided
Investigators ^ICMJE	Not Provided
Information Provided By	Trakya University
Verification Date	September 2009
^ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP

To Top